Watch when CEO Hanna Sjöström and CFO David Folkesson presented Neola Medical’s Q3-report of 2024. Learn more about the company’s financial position and the progress from this quarter, toward market approval in the U.S. After the presentation a brief Q&A follows....
Redeye initiates coverage of Neola Medical with a fair value estimate of SEK 3.1 per share in the base case scenario and SEK 5.8 per share in the bull case scenario. Read the entire coverage report by Redeye here: Redeye coverage report of Neola Medical
CEO Hanna Sjöström had the pleasure of sharing Neola Medical’s inspiring journey—from groundbreaking research at Lund University, to becoming a startup at Medicon Village, to scaling up as a NOME graduate. A huge thank you to Medicon Village and the Nordic Mentor...
When SEB’s Co-Head of Retail Banking, Mika Burman Götz, visited Neola Medical’s headquarters in Lund, she was not only surrounded by innovation and cutting-edge research but also witnessed a vision for the future of modern healthcare—where technological...
Neola Medical’s expansion in the U.S. market is gaining momentum, with significant progress in launch preparations. As part of the company’s strategy to leverage U.S. market expertise, Neola Medical has appointed Monica Alfaro Welling as its first American board...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPersonal Data Policy
